Cargando…

Molecular determinants of post-mastectomy breast cancer recurrence

Breast cancer (BC) adjuvant therapy after mastectomy in the setting of 1–3 positive lymph nodes has been controversial. This retrospective Translational Breast Cancer Research Consortium study evaluated molecular aberrations in primary cancers associated with locoregional recurrence (LRR) or distant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keene, Kimberly S., King, Tari, Hwang, E. Shelley, Peng, Bo, McGuire, Kandace P., Tapia, Coya, Zhang, Hong, Bae, Sejong, Nakhlis, Faina, Klauber-Demore, Nancy, Meszoely, Ingrid, Sabel, Michael S., Willey, Shawna C., Eterovic, Agda Karina, Hudis, Cliff, Wolff, Antonio C., De Los Santos, Jennifer, Thompson, Alastair, Mills, Gordon B., Meric-Bernstam, Funda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185974/ https://www.ncbi.nlm.nih.gov/pubmed/30345349 http://dx.doi.org/10.1038/s41523-018-0089-z

Ejemplares similares

ClinSeK: a targeted variant characterization framework for clinical sequencing
por: Zhou, Wanding, et al.
Publicado: (2015)

Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2020)

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
por: Skinner, Heath D, et al.
Publicado: (2013)

Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
por: Dominici, Laura S, et al.
Publicado: (2012)

Molecular biology of breast cancer metastasis: The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer
por: Clare, Susan E, et al.
Publicado: (2000)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Targeting MYC for triple-negative breast cancer treatment
por: Klauber-DeMore, Nancy, et al.
Publicado: (2018)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

A rare case of tumor-to-tumor metastasis: breast cancer metastatic to a benign renal mass
por: Diego, Emilia, et al.
Publicado: (2013)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2019)

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2017)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Abstract 61: Hyperbaric Oxygen Therapy Does Not Decrease Progression of Skin Flap and Nipple Areolar Ischemia to Necrosis in Nipple-sparing Mastectomy
por: Sosin, Michael, et al.
Publicado: (2018)

The Value of a Second Opinion for Breast Cancer Patients Referred to a National Cancer Institute (NCI)-Designated Cancer Center with a Multidisciplinary Breast Tumor Board
por: Garcia, Denise, et al.
Publicado: (2018)

Functional consequence of the MET-T1010I polymorphism in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Eat, sleep, play: health behaviors and their association with psychological health among cancer survivors in a nationally representative sample
por: Glasgow, Trevin E., et al.
Publicado: (2022)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Is Ptosis Inadequate as Selection Criteria? The Midclavicle-to-Inframammary Fold Distance Predicts Ischemic Complications in the Inframammary Approach to Nipple-sparing Mastectomy
por: Luvisa, Kyle, et al.
Publicado: (2019)

Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites
por: Walji, Muhammad, et al.
Publicado: (2004)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing
por: Leighton, Jake, et al.
Publicado: (2022)

Optimizing ultrasound molecular imaging of secreted frizzled related protein 2 expression in angiosarcoma
por: Tsuruta, James K., et al.
Publicado: (2017)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
por: Yeh, Elizabeth S., et al.
Publicado: (2017)

Copy Number Variation in Inflammatory Breast Cancer
por: Hazra, Aditi, et al.
Publicado: (2023)

Antibody-drug conjugates in lung cancer: dawn of a new era?
por: Coleman, Niamh, et al.
Publicado: (2023)

MON-532 Characterization of the Angiogenic Factor SFRP2 in Papillary Thyroid Carcinoma
por: Wofford, Wyatt O, et al.
Publicado: (2020)

Prophylactic mastectomy and occult malignancy: Surgical and imaging considerations
por: Thompson, Jessica L., et al.
Publicado: (2022)

CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
por: Mao, Yong, et al.
Publicado: (2013)

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2015)

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2016)

Ultrasound Molecular Imaging of Secreted Frizzled Related Protein-2 Expression in Murine Angiosarcoma
por: Tsuruta, James K., et al.
Publicado: (2014)

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
por: Huang, Licai, et al.
Publicado: (2022)

Surveillance Mammography Behaviors in Black and White Breast Cancer Survivors: Behavioral Risk Factors and Surveillance System, 2016
por: Edmonds, Megan C., et al.
Publicado: (2023)

Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types
por: Chen, Tenghui, et al.
Publicado: (2016)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vgq4nhorisnahcnvq97cs3e2kq